Christine Simmon Reacts to the Release of FDA's Biosimilars Action Plan
Christine Simmon, Executive Director of AAM's Biosimilars Council, reacts to the recent release of FDA's Biosimilars Action Plan
AAM Statement on FDA’s Biosimilars Action Plan
Agency’s Commitment to Competition, Efficient Development and Approval Process Lauded
Generic and Biosimilar Competition Is Cornerstone of President Trump’s Blueprint to Lower Drug Prices for American Patients
Administration’s Plan Embraces Getting More Generic and Biosimilar Medicines to Patients
WASHINGTON DC (May 11, 2018) – In President Trump’s remarks today at the White House, he made clear the essential role that generic and biosimilar medicines play in containing prescription drug costs for patients.
AAM Responds to President Trump's Speech on Lowering Prescription Drug Prices
The Biosimilars Council Congressional Briefing: Five Takeaways
Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion with Molly Burich (Boehringer Ingelheim), Mark Fleury (American Cancer Society’s Cancer Action Network), Greg Gierer (America’s Health Insurance Plans) and Patrick Vallano (Mylan).
A Conference You Don't Want to Miss — GRx+Biosims 2018
Biosimilars Handbook
The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products
Biosimilars hold the key to ensuring affordable access to biologic medicines for all consumers. The Biosimilars Council exists to educate, advocate, and promote the development of these products through resources such as this handbook.
This handbook is designed to be a reference tool for health care professionals as well as patients interested in learning more about biosimilars and interchangeable biologics.
Policy Recommendations to Develop a Robust Biosimilars Market in the U.S.
Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to cultivate a robust market, an additional 1.2 million patients will have access to biologic medicines, while also saving an estimated $54 billion over the next 10 years.
Skyrocketing Drug Prices: What's Driving Up Costs?
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.
AAM Issue Brief: Biosimilars Medicare Part B
The Biosimilars Council Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Status in the Medicare Part B Program
Despite the importance of biosimilars to reducing the cost of medicine, policymakers recently included a provision in a proposed bill that would have prohibited biosimilars from receiving pass-through status in Medicare Part B.